SAREPTA THERAPEUTICS

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

11 Mar 2025 07:19:10 By NetDania Notify

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

10 Mar 2025 07:33:53 By NetDania Notify

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

04 Mar 2025 06:46:51 By NetDania Notify

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

03 Mar 2025 12:38:11 By NetDania Notify

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

27 Feb 2025 06:45:10 By NetDania Notify

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

18 Feb 2025 06:47:18 By NetDania Notify

NetDania - New 12 months High: SAREPTA THERAPEUTICS INC. - COMMON STOCK

21 Jun 2024 06:45:14 By NetDania Notify

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2023 15:20:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

09 Jan 2023 10:28:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Dec 2022 14:58:49 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

28 Nov 2022 04:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

23 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments

02 Nov 2022 13:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Oct 2022 15:00:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

26 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022

07 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2022 15:15:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

29 Sep 2022 05:30:00 By Nasdaq GlobeNewswire